• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MAGE-C2通过E3连接酶MDM2和TRIM28在p53泛素化和细胞增殖中的双重作用

The Dual Roles of MAGE-C2 in p53 Ubiquitination and Cell Proliferation Through E3 Ligases MDM2 and TRIM28.

作者信息

Liu Yunshan, Cao Beibei, Hu Liqiao, Ye Jingjing, Tian Wei, He Xiaojing

机构信息

Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.

出版信息

Front Cell Dev Biol. 2022 Jul 19;10:922675. doi: 10.3389/fcell.2022.922675. eCollection 2022.

DOI:10.3389/fcell.2022.922675
PMID:35927984
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9344466/
Abstract

The tumor suppressor p53 is critical for the maintenance of genome stability and protection against tumor malignant transformation, and its homeostasis is usually regulated by ubiquitination. MDM2 is a major E3 ligase of p53 ubiquitination, and its activity is enhanced by TRIM28. TRIM28 also independently ubiquitinates p53 as an E3 ligase activated by MAGE-C2. Moreover, MAGE-C2 is highly expressed in various cancers, but the detailed mechanisms of MAGE-C2 involved in MDM2/TRIM28-mediated p53 ubiquitination remain unknown. Here, we found that MAGE-C2 directly interacts with MDM2 through its conserved MHD domain to inhibit the activity of MDM2 on p53 ubiquitination. Furthermore, TRIM28 acts as an MAGE-C2 binding partner and directly competes with MAGE-C2 for MDM2 interaction, thus releasing the inhibitory role of MAGE-C2 and promoting p53 ubiquitination. MAGE-C2 suppresses cell proliferation in TRIM28-deficient cells, but the overexpression of TRIM28 antagonizes the inhibitory role of MAGE-C2 and accumulates p53 ubiquitination to promote cell proliferation. This study clarified the molecular link of MAGE-C2 in two major E3 systems MDM2 and TRIM28 on p53 ubiquitination. Our results revealed the molecular function of how MAGE-C2 and TRIM28 contribute to p53 ubiquitination and cell proliferation, in which MAGE-C2 acts as a potential inhibitor of MDM2 and TRIM28 is a vital regulator for MAGE-C2 function in p53 protein level and cell proliferation. This work would be helpful to understand the regulation mechanism of tumor suppressor p53.

摘要

肿瘤抑制因子p53对于维持基因组稳定性和防止肿瘤恶性转化至关重要,其稳态通常由泛素化调节。MDM2是p53泛素化的主要E3连接酶,TRIM28可增强其活性。TRIM28还作为由MAGE-C2激活的E3连接酶独立地使p53泛素化。此外,MAGE-C2在多种癌症中高表达,但MAGE-C2参与MDM2/TRIM28介导的p53泛素化的详细机制仍不清楚。在此,我们发现MAGE-C2通过其保守的MHD结构域直接与MDM2相互作用,以抑制MDM2对p53泛素化的活性。此外,TRIM28作为MAGE-C2的结合伴侣,直接与MAGE-C2竞争MDM2相互作用,从而释放MAGE-C2的抑制作用并促进p53泛素化。MAGE-C2在TRIM28缺陷型细胞中抑制细胞增殖,但TRIM28的过表达拮抗MAGE-C2的抑制作用并积累p53泛素化以促进细胞增殖。本研究阐明了MAGE-C2在MDM2和TRIM28这两个主要E3系统中对p53泛素化的分子联系。我们的结果揭示了MAGE-C2和TRIM28如何促进p53泛素化和细胞增殖的分子功能,其中MAGE-C2作为MDM2的潜在抑制剂,而TRIM28是p53蛋白水平和细胞增殖中MAGE-C2功能的重要调节因子。这项工作将有助于理解肿瘤抑制因子p53的调控机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eef2/9344466/9765a91a1b0e/fcell-10-922675-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eef2/9344466/95b2813c5544/fcell-10-922675-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eef2/9344466/ad497283cc32/fcell-10-922675-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eef2/9344466/b33cdbf7f28c/fcell-10-922675-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eef2/9344466/6add71c44202/fcell-10-922675-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eef2/9344466/9765a91a1b0e/fcell-10-922675-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eef2/9344466/95b2813c5544/fcell-10-922675-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eef2/9344466/ad497283cc32/fcell-10-922675-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eef2/9344466/b33cdbf7f28c/fcell-10-922675-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eef2/9344466/6add71c44202/fcell-10-922675-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eef2/9344466/9765a91a1b0e/fcell-10-922675-g005.jpg

相似文献

1
The Dual Roles of MAGE-C2 in p53 Ubiquitination and Cell Proliferation Through E3 Ligases MDM2 and TRIM28.MAGE-C2通过E3连接酶MDM2和TRIM28在p53泛素化和细胞增殖中的双重作用
Front Cell Dev Biol. 2022 Jul 19;10:922675. doi: 10.3389/fcell.2022.922675. eCollection 2022.
2
MAGE-A Cancer/Testis Antigens Inhibit MDM2 Ubiquitylation Function and Promote Increased Levels of MDM4.黑色素瘤相关抗原A(MAGE-A)癌胚抗原抑制MDM2泛素化功能并促进MDM4水平升高。
PLoS One. 2015 May 22;10(5):e0127713. doi: 10.1371/journal.pone.0127713. eCollection 2015.
3
Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase.NEDD4-1 E3 连接酶对 Mdm2 蛋白稳定性和 p53 反应的调节。
Oncogene. 2015 Jan 15;34(3):281-9. doi: 10.1038/onc.2013.557. Epub 2014 Jan 13.
4
Sequential ubiquitination of p53 by TRIM28, RLIM, and MDM2 in lung tumorigenesis.TRIM28、RLIM和MDM2在肺癌发生过程中对p53的顺序泛素化作用
Cell Death Differ. 2021 Jun;28(6):1790-1803. doi: 10.1038/s41418-020-00701-y. Epub 2020 Dec 16.
5
Mdm2 Splice isoforms regulate the p53/Mdm2/Mdm4 regulatory circuit via RING domain-mediated ubiquitination of p53 and Mdm4.Mdm2剪接异构体通过RING结构域介导的p53和Mdm4泛素化来调节p53/Mdm2/Mdm4调控回路。
Cell Cycle. 2017 Apr 3;16(7):660-664. doi: 10.1080/15384101.2017.1288327. Epub 2017 Feb 6.
6
Dual-site regulation of MDM2 E3-ubiquitin ligase activity.MDM2 E3泛素连接酶活性的双位点调控。
Mol Cell. 2006 Jul 21;23(2):251-63. doi: 10.1016/j.molcel.2006.05.029.
7
MDM2 protein-mediated ubiquitination of numb protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism.MDM2 蛋白介导的 numb 蛋白泛素化:鉴定 MDM2 的第二个生理底物,该底物采用双位点对接机制。
J Biol Chem. 2012 Apr 20;287(17):14052-68. doi: 10.1074/jbc.M111.303875. Epub 2012 Feb 15.
8
RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction.RNF12通过靶向MDM2进行降解,促进p53依赖的细胞生长抑制和凋亡。
Cancer Lett. 2016 May 28;375(1):133-141. doi: 10.1016/j.canlet.2016.02.013. Epub 2016 Feb 27.
9
Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.MDM2 E3 连接酶活性的乙酰化依赖性调节决定了其致癌功能。
Sci Signal. 2017 Feb 14;10(466):eaai8026. doi: 10.1126/scisignal.aai8026.
10
Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.突变型 p53 与 MDM2 酸性结构域结合抑制 E3 连接酶活性。
Mol Cell Biol. 2019 Feb 4;39(4). doi: 10.1128/MCB.00375-18. Print 2019 Feb 15.

引用本文的文献

1
ALDH4A1 knockdown inhibits in vitro atherosclerosis model by modulating Trim28-mediated P53 ubiquitination to suppress ferroptosis of vascular endothelial cells.醛脱氢酶4A1(ALDH4A1)基因敲低通过调节Trim28介导的P53泛素化抑制血管内皮细胞铁死亡,从而抑制体外动脉粥样硬化模型。
In Vitro Cell Dev Biol Anim. 2025 Aug 13. doi: 10.1007/s11626-025-01102-6.
2
A novel indirubin- 3-monoxime derivative I3MV- 8b exhibits remarkable cytotoxicity against multiple myeloma by targeting TRIM28.一种新型靛玉红-3-单肟衍生物I3MV-8b通过靶向TRIM28对多发性骨髓瘤表现出显著的细胞毒性。
Biomark Res. 2025 Apr 7;13(1):57. doi: 10.1186/s40364-025-00773-3.
3

本文引用的文献

1
Sequential ubiquitination of p53 by TRIM28, RLIM, and MDM2 in lung tumorigenesis.TRIM28、RLIM和MDM2在肺癌发生过程中对p53的顺序泛素化作用
Cell Death Differ. 2021 Jun;28(6):1790-1803. doi: 10.1038/s41418-020-00701-y. Epub 2020 Dec 16.
2
p53-R273H promotes cancer cell migration via upregulation of neuraminidase-1.p53-R273H通过上调神经氨酸酶-1促进癌细胞迁移。
J Cancer. 2020 Oct 4;11(23):6874-6882. doi: 10.7150/jca.44718. eCollection 2020.
3
Structural basis for substrate recognition and chemical inhibition of oncogenic MAGE ubiquitin ligases.
PPIXpress and PPICompare webservers infer condition-specific and differential PPI networks.
PPIXpress和PPICompare网络服务器推断特定条件下的和差异蛋白质-蛋白质相互作用网络。
Bioinform Adv. 2025 Feb 11;5(1):vbaf003. doi: 10.1093/bioadv/vbaf003. eCollection 2025.
4
TRIM28 in cancer and cancer therapy.TRIM28与癌症及癌症治疗
Front Genet. 2024 Jul 19;15:1431564. doi: 10.3389/fgene.2024.1431564. eCollection 2024.
5
Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer.癌睾丸抗原:利用癌症基因组不稳定性的新兴治疗靶点。
Mol Ther Oncol. 2024 Jan 26;32(1):200768. doi: 10.1016/j.omton.2024.200768. eCollection 2024 Mar 21.
6
Establishing the Link between X-Chromosome Aberrations and Status, with Breast Cancer Patient Outcomes.建立 X 染色体异常与乳腺癌患者预后的关联。
Cells. 2023 Sep 11;12(18):2245. doi: 10.3390/cells12182245.
7
The SUMOylation and ubiquitination crosstalk in cancer.癌症中的类泛素化修饰与泛素化修饰之间的相互作用
J Cancer Res Clin Oncol. 2023 Nov;149(17):16123-16146. doi: 10.1007/s00432-023-05310-z. Epub 2023 Aug 28.
8
MiRNA Differences Related to Treatment-Resistant Schizophrenia.与治疗抵抗性精神分裂症相关的 miRNA 差异。
Int J Mol Sci. 2023 Jan 18;24(3):1891. doi: 10.3390/ijms24031891.
致癌 MAGE 泛素连接酶的底物识别和化学抑制的结构基础。
Nat Commun. 2020 Oct 1;11(1):4931. doi: 10.1038/s41467-020-18708-x.
4
Emerging roles of the MAGE protein family in stress response pathways.MAGE 蛋白家族在应激反应途径中的新作用。
J Biol Chem. 2020 Nov 20;295(47):16121-16155. doi: 10.1074/jbc.REV120.008029. Epub 2020 Sep 13.
5
KLHL4, a novel p53 target gene, inhibits cell proliferation by activating p21.KLHL4,一个新的 p53 靶基因,通过激活 p21 抑制细胞增殖。
Biochem Biophys Res Commun. 2020 Sep 24;530(3):588-596. doi: 10.1016/j.bbrc.2020.07.100. Epub 2020 Aug 1.
6
Silencing of p53 reduces cell migration in human Tenon's fibroblasts induced by TGF-β.p53 沉默可减少 TGF-β诱导的人眼Tenon's 成纤维细胞的迁移。
Int Ophthalmol. 2020 Jun;40(6):1509-1516. doi: 10.1007/s10792-020-01320-9. Epub 2020 Mar 2.
7
The role of amplification and overexpression in therapeutic resistance of malignant tumors.扩增和过表达在恶性肿瘤治疗耐药中的作用。
Cancer Cell Int. 2019 Aug 22;19:216. doi: 10.1186/s12935-019-0937-4. eCollection 2019.
8
p53 suppression is essential for oncogenic SPAG5 upregulation in lung adenocarcinoma.p53 抑制对于肺腺癌中致癌基因 SPAG5 的上调至关重要。
Biochem Biophys Res Commun. 2019 May 28;513(2):319-325. doi: 10.1016/j.bbrc.2019.03.198. Epub 2019 Apr 5.
9
Cancer‑testis antigen HCA587/MAGEC2 interacts with the general transcription coactivator TAF9 in cancer cells.癌症-睾丸抗原 HCA587/MAGEC2 与肿瘤细胞中的一般转录共激活因子 TAF9 相互作用。
Mol Med Rep. 2018 Feb;17(2):3226-3231. doi: 10.3892/mmr.2017.8260. Epub 2017 Dec 12.
10
DNA damage responses and p53 in the aging process.衰老过程中的 DNA 损伤反应和 p53。
Blood. 2018 Feb 1;131(5):488-495. doi: 10.1182/blood-2017-07-746396. Epub 2017 Nov 15.